Argomento non disponibile
Panoramica
Select a topic to solve related cases or follow a course topic
-
Topic 1Long COVID
-
Topic 2Immunotherapy and antibody-drug conjugates: handling AEs and special populations
-
Topic 3First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 4Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 5Adjuvant treatment approaches for MIBC
-
Topic 6NEW --- Molecular diagnostics in the era of targeted therapies for mUCa
-
Topic 7COVID-19 vaccines
-
Topic 8Treatment of acute COVID-19
-
Topic 9Acute COVID-19 in special populations
-
Topic 10CRPC: treatment in daily clinical practice
-
Topic 11Gestione iniziale del dolore dovuto a osteoartrite
-
Topic 12Osteoartrite: quali opzioni considerare dopo un fallimento terapeutico?
-
Topic 13Gestione del dolore associato a osteoartrite in pazienti con comorbilità
-
Topic 14Invio a consulto specialistico e follow-up del dolore cronico associato a osteoartrite
-
Topic 15High-risk non-metastatic prostate cancer
-
Topic 16Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 17Finding the right ADT for the right patient
-
Topic 18Initial treatment of MIBC
-
Topic 19Biochemical recurrence after radical prostatectomy
-
Topic 20mCRPC: novel and emerging agents
-
Topic 21Treatment of low and intermediate-risk PCa
-
Topic 22Active surveillance: yes or no?
-
Topic 23Adverse pathology at radical prostatectomy
-
Topic 24Finding the right ADT for the right patient
-
Topic 25Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 26NEW---High-risk non-metastatic prostate cancer
-
Topic 27Management of non-neurogenic female OAB
-
Topic 28Initial management of nocturia
-
Topic 29Male LUTS: keep on learning
-
Topic 30New hope for patients progressing after prior treatment for mUCa
-
Topic 31Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 32Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 33Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 34First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 35UPDATED --- Systemic therapy for HER2-positive early breast cancer
-
Topic 36Systemic therapy for mRCC: second line and beyond
-
Topic 37UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 38Management of small renal masses
-
Topic 39UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 40NEW --- Systemic therapy for early stage TNBC
-
Topic 41Local therapy for mRCC
-
Topic 42UPDATED --- Radiotherapy for early breast cancer
-
Topic 43Management of HER2+ MBC
-
Topic 44Brain metastases in patients with HER2+ breast cancer
-
Topic 45CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 46Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 47Challenges in high-risk NMIBC